Preparation method and application of methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterials
Through the preparation of methotrexate-menthol-mounted photosensitizer IR780 folic acid-targeted nanomaterials, the problems of insufficient targeting and low ultrasound diagnosis rate in tumor treatment are solved, and targeted imaging and combination are achieved Photothermal treatment improves treatment efficiency.
Patent Information
- Application Number
- CN202310150093.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-02-22
AI Technical Summary
Traditional nanomaterials for diagnosis and treatment have problems in tumor treatment, insufficient tumor killing ability of single treatment, and low ultrasound diagnosis rate.
The preparation method of the folic acid-targeted self-assembled nanomaterials with methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterials is formed through esterification reaction and self-assembly technology to form an amphiphilic drug-drug combination to achieve high expression of targeted folic acid receptors Photothermal combined with chemotherapy and ultrasound imaging of tumors.
It improves the targeting and treatment efficiency of drugs, realizes targeted imaging of tumors and combined with photothermal therapy, enhances the killing ability of tumor cells, and improves the ultrasound diagnosis rate.
Smart Images

Figure CN116251184B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of near-infrared light therapy of tumor photothermal agents, and in particular to a preparation method and application of an amphiphilic drug molecule self-assembly nanomaterial encapsulating a photosensitizer IR780. Background Art
[0002] The incidence and mortality of malignant tumors are increasing year by year. It is one of the main disease spectrums that threaten human life and health. Therefore, early diagnosis and treatment of malignant tumors are particularly critical. At present, the treatment methods for tumors mainly include chemotherapy, radiotherapy and surgical treatment, but these methods have large side effects and patients often cannot tolerate them. Therefore, exploring a new type of nanomaterial that integrates diagnosis and treatment with chemotherapy, photothermal therapy and targeted ultrasound imaging is one of the research hotspots in tumor treatment and has broad clinical application value.
[0003] Photothermal therapy (PTT) refers to a treatment method in which photothermal agents can absorb radiation energy in a specific band and convert it into thermal energy. Nanomaterials rich in photosensitizers are enriched in the tumor site due to their targeting, and near-infrared irradiation is performed on the tumor site to achieve high heat in the tumor site, causing irreversible damage to the cancer cell membrane and inducing protein denaturation, thereby killing tumor cells.
[0004] Amphiphilic drug-drug conjugates (ADDCs) have the ability to self-assemble into nanoscale drugs in aqueous solution, showing great potential in the diagnosis and treatment of diseases. Photosensitizer IR780 has good photothermal conversion ability, but as a hydrophobic small molecule, it is not conducive to its bioavailability.
[0005] At present, traditional diagnostic and therapeutic nanomaterials have problems in the process of tumor treatment, such as lack of targeting, insufficient tumor killing ability of single treatment, and low ultrasound diagnosis rate. Therefore, it is urgent to develop a new type of integrated diagnostic and therapeutic nanomaterial to solve the above problems. Summary of the invention
[0006] The purpose of the present invention is to solve the problems of lack of targeting, insufficient tumor killing ability of single treatment and low ultrasound diagnosis rate of traditional diagnostic and therapeutic nanomaterials in the process of tumor treatment, and to provide a preparation method and application of methotrexate-menthol photosensitizer IR780 folic acid targeted self-assembled nanomaterials.
[0007] The preparation method of methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial is carried out according to the following steps:
[0008] First, methotrexate and menthol are subjected to esterification reaction under catalytic conditions, and a crude methotrexate-menthol reactant is obtained by vacuum drying, washing and filtering; then, the crude methotrexate-menthol reactant is purified by column chromatography, and then mixed with a dimethyl sulfoxide solution to obtain a DMSO solution of a methotrexate-menthol conjugate; the DMSO solution of the methotrexate-menthol conjugate is self-assembled with a DMSO solution of IR780, and finally centrifuged and washed to obtain a methotrexate-menthol photosensitizer IR780 folic acid targeted self-assembled nanomaterial.
[0009] Application of methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterials, and application of the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterials in the preparation of anti-tumor drugs and ultrasound imaging materials for photothermal combined chemotherapy targeting tumors with high expression of folate receptors.
[0010] Beneficial effects of the present invention:
[0011] (1) The preparation method of the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterial of the present invention is to combine the esterification reaction of methotrexate and menthol to prepare an amphiphilic drug-drug conjugate, further form a prodrug nanosphere through self-assembly, and self-assemble with the photosensitizer IR780 under the hydrophobic force. The hydrophilic methotrexate is used as a folic acid analogue, which can actively target tumors with high folic acid expression. Under near-infrared irradiation, the photosensitizer's photothermal conversion ability is used as photothermal therapy to kill tumor cells. The heat-sensitive phase change material menthol undergoes a liquid-gas phase change under the thermal effect of the photosensitizer to achieve the effect of ultrasound contrast. At the same time, the prepared methotrexate-menthol-loaded IR780 is nanometer-level and has good biocompatibility. It can be used for targeted imaging and chemical combined photothermal therapy of tumors, solving the problems of traditional diagnostic and therapeutic nanomaterials in the process of tumor treatment, lack of targeting, insufficient tumor killing ability of single treatment, and low ultrasound diagnosis rate.
[0012] (2) The drugs in the present invention have the following advantages by self-assembling into clear nanostructures: Since the amphiphilic drug-drug conjugate can achieve self-delivery of the drug, no additional carrier is needed, and the drug delivery efficiency can be greatly improved. The methotrexate-menthol drug-drug conjugate is linked by an ester bond, has good biocompatibility and pH sensitivity, and the ester bond decomposes in the weakly acidic tumor environment to achieve the purpose of targeted drug release. IR as a photosensitizer has high photothermal conversion performance and can be used for near-infrared radiation-induced thermal ablation treatment of tumors. The increase in local tumor temperature can also further promote the rupture of ester bonds and the phase change vaporization of menthol. Therefore, the present invention rationally combines chemotherapy drugs, phase change materials, and photosensitizers to achieve targeted ultrasound imaging and chemical combined photothermal therapy of tumors.
[0013] (3) The present invention utilizes the property of amphiphilic substances to self-assemble into spheres, synthesizes the chemotherapy drug methotrexate-phase change material menthol amphiphilic molecules, and encapsulates IR780 therein, which is better used for imaging and treatment of tumors, enriching the types of nanomaterials for tumor targeted therapy based on amphiphilic drug-drug conjugate self-assembly, and can provide more personalized and precise diagnosis and treatment plans for tumor patients.
[0014] The invention can obtain a preparation method and application of a methotrexate-menthol-carried photosensitizer IR780 folic acid targeted self-assembly nano material. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is a scanning electron microscope image (SEM) of the methotrexate-menthol self-assembled nanomaterial obtained in Example 1;
[0016] Figure 2 This is a scanning electron microscope image (SEM) of the methotrexate-menthol photosensitizer IR780 folic acid targeted self-assembled nanomaterial obtained in Example 1;
[0017] Figure 3 The infrared (FT-IR) spectra of the methotrexate-menthol nanomaterial, the mixture of methotrexate and menthol in an equal molar ratio, menthol, and methotrexate obtained in Example 1, a represents the methotrexate-menthol nanomaterial, b represents the mixture of methotrexate and menthol in an equal molar ratio, c represents menthol, and d represents methotrexate;
[0018] Figure 4 The photothermal heating curves of different concentrations of the methotrexate-menthol photosensitizer IR780 self-assembled nanomaterials obtained in Example 1 and deionized water under 808nm near-infrared light (2 W / cm2), ● represents 500μg / mL, ■ represents 250μg / mL, ▲ represents 100μg / mL, ▼ represents 50μg / mL, and ◆ represents deionized water. DETAILED DESCRIPTION
[0019] Specific implementation method 1: The preparation method of the methotrexate-menthol photosensitizer IR780 folic acid targeted self-assembled nanomaterial in this implementation method is carried out according to the following steps:
[0020] First, methotrexate and menthol are subjected to esterification reaction under catalytic conditions, and a crude methotrexate-menthol reactant is obtained by vacuum drying, washing and filtering; then, the crude methotrexate-menthol reactant is purified by column chromatography, and then mixed with a dimethyl sulfoxide solution to obtain a DMSO solution of a methotrexate-menthol conjugate; the DMSO solution of the methotrexate-menthol conjugate is self-assembled with a DMSO solution of IR780, and finally centrifuged and washed to obtain a methotrexate-menthol photosensitizer IR780 folic acid targeted self-assembled nanomaterial.
[0021] Specific embodiment 2: This embodiment differs from specific embodiment 1 in that: the specific steps of carrying out esterification reaction of methotrexate and menthol under catalytic conditions are as follows: methotrexate, N,N'-dicyclohexylcarboximide and 4-dimethylaminopyridine are added to anhydrous dimethylformamide solution, and stirred for reaction for 30 to 60 minutes under an argon protective atmosphere at -10°C to 10°C to obtain solution A, wherein the mass ratio of methotrexate, N,N'-dicyclohexylcarboximide, 4-dimethylaminopyridine to the volume of anhydrous dimethylformamide solution is (400 to 500) mg: (20 0~300)mg:(150~180)mg:(10~20)mL; adding menthol to anhydrous dimethylformamide solution and fully dissolving to obtain solution B, wherein the ratio of the mass of menthol to the volume of anhydrous dimethylformamide solution is (150~200)mg:(2~4)mL; adding solution B dropwise to solution A, stirring at a speed of 500~1000rpm for 48~72h under light-proof conditions at 25~30℃ to obtain solution C, wherein the mass ratio of methotrexate to menthol in solution C is (450~480):(150~180).
[0022] The other steps are the same as those in the first specific implementation.
[0023] Specific embodiment three: The difference between this embodiment and specific embodiment one or two is that the specific steps of vacuum drying, washing and filtering after the esterification reaction are as follows: filter out the white solid in solution C, dry the filtrate in a vacuum environment at 40-60°C, wash the dried sample and discard the filtrate to obtain a crude methotrexate-menthol reactant.
[0024] The other steps are the same as those in the first or second embodiment.
[0025] Specific embodiment 4: The difference between this embodiment and specific embodiments 1 to 3 is that the specific steps of washing are: first, the dried sample is washed with an ethyl acetate solution cooled at -60°C to -80°C, and the filtrate is discarded; then the sample is washed 2 to 3 times with dichloromethane, and the filtrate is discarded to obtain a crude methotrexate-menthol reaction product.
[0026] The other steps are the same as those in Specific Embodiments 1 to 3.
[0027] Specific embodiment 5: The difference between this embodiment and specific embodiments 1 to 4 is that the specific steps of purifying the crude methotrexate-menthol reaction product by column chromatography are as follows: ethyl acetate and methanol in a volume ratio of (1 to 1.5): 1 are used as developing solvents, ethyl acetate and methanol are used as initial eluents, and then ethyl acetate and methanol are used in a volume ratio of (5:1), (4:1), (3:1) and (2:1) in sequence to gradient elute the crude methotrexate-menthol reaction product, and rotary evaporate to obtain a purified methotrexate-menthol conjugate.
[0028] The other steps are the same as those in Specific Embodiments 1 to 4.
[0029] Specific embodiment 6: This embodiment differs from specific embodiments 1 to 5 in that the specific steps of self-assembling the DMSO solution of methotrexate-menthol conjugate and the DMSO solution of IR780 are as follows: under light-proof conditions, the DMSO solution of IR780 is added to the DMSO solution of methotrexate-menthol conjugate, and stirred at a temperature of 25 to 30° C. at a speed of 200 to 400 rpm for 5 to 10 minutes to obtain a solution D, in which the photosensitizer IR780 The mass ratio of the purified methotrexate-menthol conjugate to the purified methotrexate-menthol conjugate is 1:1; at a rotation speed of 200-400 rpm, deionized water is added dropwise into solution D at a dropping speed of 1 drop / second. After stirring for 24-48 hours, a nano-spherical methotrexate-menthol photosensitizer IR780 material dispersion is obtained. The mass ratio of the purified methotrexate-menthol conjugate to the volume of deionized water in the nano-spherical methotrexate-menthol photosensitizer IR780 material dispersion is 5 mg: (5-10) mL.
[0030] The other steps are the same as those in Specific Embodiments 1 to 5.
[0031] Specific embodiment seven: The difference between this embodiment and any one of specific embodiments one to six is that the preparation steps of the DMSO solution of methotrexate-menthol conjugate are as follows: under the temperature condition of 25-30°C, the purified methotrexate-menthol conjugate is added to the dimethyl sulfoxide solution, and stirred at a speed of 200-400 rpm for 5-10 min to obtain the DMSO solution of the methotrexate-menthol conjugate, and the ratio of the mass of the purified methotrexate-menthol conjugate to the volume of the dimethyl sulfoxide solution is (5-10) mg:1 mL.
[0032] The other steps are the same as those in Specific Embodiments 1 to 6.
[0033] Specific embodiment eight: The difference between this embodiment and specific embodiments one to seven is that the preparation steps of the DMSO solution of IR780 are as follows: under light-proof conditions at 25 to 30° C., add the photosensitizer IR780 to the dimethyl sulfoxide solution, and stir at a speed of 200 to 400 rpm for 5 to 10 min to obtain the DMSO solution of IR780, wherein the ratio of the mass of the photosensitizer IR780 to the volume of the dimethyl sulfoxide solution is (5 to 10) mg: 1 mL.
[0034] The other steps are the same as those in Specific Embodiments 1 to 7.
[0035] Specific embodiment nine: The difference between this embodiment and specific embodiments one to eight is that the specific steps of centrifugation and washing of the nano-spherical methotrexate-menthol photosensitizer IR780 material dispersion are as follows: the nano-spherical methotrexate-menthol material dispersion is centrifuged at a speed of 10,000 to 15,000 rpm for 5 to 10 minutes, washed with deionized water after centrifugation, and the above centrifugation and washing operations are repeated twice to obtain the methotrexate-menthol nanomaterial.
[0036] The other steps are the same as those in Specific Embodiments 1 to 8.
[0037] Specific embodiment ten: This embodiment describes the application of methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterials, and the application of the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterials in the preparation of anti-tumor drugs and ultrasound imaging materials for photothermal combined chemotherapy targeting tumors with high expression of folate receptors.
[0038] The following examples are used to verify the beneficial effects of the present invention:
[0039] Example 1: A method for preparing methotrexate-menthol-loaded photosensitizer IR780 folic acid-targeted self-assembled nanomaterials, according to the following steps:
[0040] Step 1: esterification reaction of methotrexate and menthol under catalytic conditions, vacuum drying, washing and filtering;
[0041] 454.4 mg of methotrexate, 268.2 mg of N,N'-dicyclohexylcarbodiimide and 158.8 mg of 4-dimethylaminopyridine were placed in a 50 mL round-bottom flask, and then 15 mL of anhydrous dimethylformamide solution was added, and the mixture was stirred for 40 min under an argon protective atmosphere at 0°C to obtain solution A. 171.9 mg of menthol was added to 2.5 mL of anhydrous dimethylformamide solution, and after being fully dissolved, solution B was obtained. Solution B was added dropwise to solution A, and stirred at 600 rpm for 72 h under light-proof conditions at 30°C to obtain solution C, which was a methotrexate-menthol conjugate containing an ester bond. The white solid in solution C was filtered off, and the filtrate was placed in a crystallization dish and vacuum dried, and the temperature was set to 50°C. The dried sample was collected and first washed with 30 mL of ethyl acetate solution cooled at -80°C, and the filtrate was discarded by suction; then the sample was washed three times with 30 mL of dichloromethane, and the filtrate was discarded by suction to obtain about 300 mg of a crude methotrexate-menthol reaction product.
[0042] Step 2: Purifying the crude methotrexate-menthol reaction product by column chromatography;
[0043] The crude methotrexate-menthol reaction product was gradient eluted with ethyl acetate and methanol in a volume ratio of (4:1), (3:1) and (2:1) respectively, and rotary evaporation was performed to obtain a purified methotrexate-menthol conjugate.
[0044] Step 3: self-assemble the DMSO solution of methotrexate-menthol conjugate with the DMSO solution of IR780, centrifuge and wash;
[0045] At a temperature of 25°C, 5 mg of purified methotrexate-menthol conjugate was added to 0.5 mL of dimethyl sulfoxide solution, and stirred at 300 rpm for 5 min to obtain a DMSO solution of methotrexate-menthol conjugate; at a light-proof condition of 25°C, 1 mg of photosensitizer IR780 (near-infrared absorbing dye) was added to 0.1 mL of dimethyl sulfoxide solution, and stirred at 300 rpm for 5 min to obtain a DMSO solution of IR780.
[0046] Under light-proof conditions, 25 μL of IR780 DMSO solution was added to 0.5 mL of methotrexate-menthol conjugate DMSO solution, and stirred at 300 rpm for 5 min at a temperature of 25-30° C. to obtain solution D. Under a rotation speed of 300 rpm, 5 mL of deionized water was added dropwise to solution D at a drop rate of 1 drop / second. After stirring for 24 hours, a nano-spherical methotrexate-menthol photosensitizer IR780 material dispersion was obtained. The nano-spherical methotrexate-menthol material dispersion was centrifuged at a rotation speed of 12000 rpm for 10 min, washed with deionized water after centrifugation, and the above centrifugation and washing operations were repeated twice to remove any residual dimethyl sulfoxide to obtain about 500 mg of methotrexate-menthol nanomaterials, 5 mL of deionized water was added, and ultrasonic dispersion was uniformly prepared to obtain a methotrexate-menthol nanomaterial with a concentration of 100 μg / mL.
[0047] Figure 1 is a scanning electron microscope image (SEM) of the methotrexate-menthol self-assembled nanomaterial obtained in Example 1; Figure 1 As shown, the obtained methotrexate-menthol self-assembled nanomaterial is a spherical structure, which proves that the amphiphilic substance methotrexate-menthol has the ability to self-assemble into stable spheres in aqueous solution.
[0048] Figure 2 This is a scanning electron microscope image (SEM) of the methotrexate-menthol photosensitizer IR780 folic acid targeted self-assembled nanomaterial obtained in Example 1; Figure 2 As shown, the obtained methotrexate-menthol-loaded photosensitizer IR780 folic acid-targeted self-assembled nanomaterial is a spherical structure, proving that the amphiphilic substance methotrexate-menthol still has the ability to self-assemble into stable spheres in aqueous solution after encapsulating IR780.
[0049] Figure 3 The infrared (FT-IR) spectra of the methotrexate-menthol nanomaterial, the mixture of methotrexate and menthol in an equal molar ratio, menthol, and methotrexate obtained in Example 1, a represents the methotrexate-menthol nanomaterial, b represents the mixture of methotrexate and menthol in an equal molar ratio, c represents menthol, and d represents methotrexate; Figure 3 As shown, the characteristic absorption peak of the ester bond can be observed in a, indicating that the methotrexate-menthol nanomaterial is successfully produced by the esterification reaction of methotrexate and menthol.
[0050] Figure 4The photothermal temperature rise curves of different concentrations of the methotrexate-menthol photosensitizer IR780 self-assembled nanomaterials prepared in Example 1 and deionized water under 808nm near-infrared light (2 watts / square centimeter), ● represents 500μg / mL, ■ represents 250μg / mL, ▲ represents 100μg / mL, ▼ represents 50μg / mL, and ◆ represents deionized water; Figure 4 As shown, the methotrexate-menthol-loaded photosensitizer IR780 self-assembled nanomaterial has photothermal heating ability, and the heating ability is concentration-dependent. As the concentration increases, the heating ability increases.
Claims
1. A method for preparing a methotrexate-menthol-loaded photosensitizer IR780 folic acid-targeted self-assembled nanomaterial, characterized in that The preparation method is carried out according to the following steps: First, methotrexate and menthol are subjected to esterification reaction under catalytic conditions, and then vacuum drying, washing and filtering are performed to obtain a crude methotrexate-menthol reaction product; The crude methotrexate-menthol reaction product is then purified by column chromatography and mixed with a dimethyl sulfoxide solution to obtain a DMSO solution of a methotrexate-menthol conjugate; The DMSO solution of the methotrexate-menthol conjugate and the DMSO solution of IR780 are self-assembled, and finally centrifuged and washed to obtain the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterial.
2. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 1, characterized in that The specific steps of carrying out esterification reaction of methotrexate and menthol under catalytic conditions are as follows: adding methotrexate, N,N'-dicyclohexylcarboximide and 4-dimethylaminopyridine to anhydrous dimethylformamide solution, stirring and reacting for 30 to 60 minutes under an argon protective atmosphere at -10°C to 10°C to obtain solution A, wherein the mass ratio of methotrexate, the mass of N,N'-dicyclohexylcarboximide, the mass of 4-dimethylaminopyridine to the volume of the anhydrous dimethylformamide solution is (400 to 500) mg: (200 to 300) mg: (150 ~180) mg: (10~20) mL; adding menthol to anhydrous dimethylformamide solution and fully dissolving to obtain solution B, wherein the ratio of the mass of menthol to the volume of anhydrous dimethylformamide solution is (150~200) mg: (2~4) mL; adding solution B dropwise to solution A, stirring at a speed of 500~1000 rpm for 48~72 h at 25~30° C. in the dark, to obtain solution C, wherein the mass ratio of methotrexate to menthol in solution C is (450~480): (150~180).
3. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 1 or 2, characterized in that The specific steps of vacuum drying, washing and filtering after the esterification reaction are as follows: filtering out the white solid in solution C, drying the filtrate in a vacuum environment at 40 to 60° C., washing the dried sample and discarding the filtrate to obtain a crude methotrexate-menthol reaction product.
4. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 3, characterized in that The specific steps of washing are: first, washing the dried sample with an ethyl acetate solution cooled at -60°C to -80°C, and discarding the filtrate; then, washing the sample with dichloromethane for 2 to 3 times, and discarding the filtrate to obtain a crude methotrexate-menthol reaction product.
5. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 1, characterized in that The specific steps of purifying the crude methotrexate-menthol reaction product by column chromatography are as follows: using ethyl acetate and methanol in a volume ratio of (1 to 1.5):1 as developing solvents, using ethyl acetate and methanol as initial eluents, and then gradient eluting the crude methotrexate-menthol reaction product with ethyl acetate and methanol in volume ratios of (5:1), (4:1), (3:1) and (2:1) in sequence, and rotary evaporating to obtain a purified methotrexate-menthol conjugate.
6. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 1, characterized in that The specific steps of self-assembling the DMSO solution of methotrexate-menthol conjugate and the DMSO solution of IR780 are as follows: under light-proof conditions, adding the DMSO solution of IR780 to the DMSO solution of methotrexate-menthol conjugate, stirring at a temperature of 25 to 30° C. and a speed of 200 to 400 rpm for 5 to 10 minutes to obtain solution D, wherein the mass ratio of photosensitizer IR780 to the purified methotrexate-menthol conjugate in the solution D is 1:1; under a speed of 200 to 400 rpm, deionized water is added dropwise to solution D at a drop speed of 1 drop / second, and after stirring for 24 to 48 hours, a nano-spherical methotrexate-menthol photosensitizer IR780 material dispersion is obtained, and the ratio of the mass of the purified methotrexate-menthol conjugate to the volume of deionized water in the nano-spherical methotrexate-menthol photosensitizer IR780 material dispersion is 5 mg: (5 to 10) mL.
7. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 1 or 6, characterized in that The preparation steps of the DMSO solution of the methotrexate-menthol conjugate are as follows: under the temperature condition of 25-30° C., the purified methotrexate-menthol conjugate is added to the dimethyl sulfoxide solution, and stirred at a speed of 200-400 rpm for 5-10 minutes to obtain the DMSO solution of the methotrexate-menthol conjugate, wherein the ratio of the mass of the purified methotrexate-menthol conjugate to the volume of the dimethyl sulfoxide solution is (5-10) mg:1 mL.
8. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 1 or 6, characterized in that The preparation steps of the DMSO solution of IR780 are as follows: under light-proof conditions at 25 to 30° C., add the photosensitizer IR780 to the dimethyl sulfoxide solution, and stir at a speed of 200 to 400 rpm for 5 to 10 minutes to obtain the DMSO solution of IR780, wherein the ratio of the mass of the photosensitizer IR780 to the volume of the dimethyl sulfoxide solution is (5 to 10) mg: 1 mL.
9. The method for preparing the methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembly nanomaterial according to claim 6, characterized in that The specific steps of centrifuging and washing the nano-spherical methotrexate-menthol photosensitizer IR780 material dispersion are as follows: the nano-spherical methotrexate-menthol material dispersion is centrifuged at a speed of 10,000 to 15,000 rpm for 5 to 10 minutes, washed with deionized water after centrifugation, and the above centrifugation and washing operations are repeated twice to obtain the methotrexate-menthol nanomaterial.
10. Use of methotrexate-menthol-loaded photosensitizer IR780 folic acid targeted self-assembled nanomaterials prepared by the method according to any one of claims 1 to 9, characterized in that The methotrexate-menthol-loaded photosensitizer IR780 folic acid-targeted self-assembled nanomaterial is used in the preparation of anti-tumor drugs and ultrasonic imaging materials for photothermal combined chemotherapy targeting tumors with high folate receptor expression.
Citation Information
Patent Citations
Ganoderan-phenylboronic acid-methotrexate conjugate drug loading nanoparticle with pH response and preparation method of nanoparticle
CN108524947A
Preparation method and application of hypericin-carboxylated carbon nanotube-zeolite-like imidazole framework nanocomposite
CN115252781A
Controlled releasing composition
WO2010066203A1
